Volitionrx Ltd (VNRX) 3.37 $VNRX
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
PR Newswire - Tue Jun 14, 6:02AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced full results from a prospective assessment of pre-analytical variables contributing to the accuracy of its NuQ® blood test that confirm the stability of circulating cell-free nucleosomes (cfnucleosomes) as biomarkers in cancer. The findings were published on 13th June 2016 in the article, "Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9me3" in the Scandinavian Journal of Clinical and Laboratory Investigation, an international scientific journal focused on clinically-orientated biochemical and physiological research.
VNRX: 3.37 (-0.07)
VolitionRx to Present at Two Upcoming Conferences in June
PR Newswire - Tue May 31, 8:16AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that the Company is scheduled to present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and at the LD Micro Invitational conference, being held June 7-9 in Los Angeles, CA.
VNRX: 3.37 (-0.07)
SeeThruEquity Issues Update Note on VolitionRx (NYSE MKT: VNRX) with a Price Target of $6.70
ACCESSWIRE - Mon May 23, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on VolitionRx Ltd. (NYSE MKT: VNRX).
VNRX: 3.37 (-0.07)
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
PR Newswire - Thu May 19, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that its Chief Medical Officer & Head of U.S. Operations, Dr. Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee Meeting on May 20, 2016, which precedes Digestive Disease Week (DDW), being held May 21-24, 2016 in San Diego, CA. Dr. Terrell will present data from three clinical trials evaluating the Company's NuQ® blood tests for the detection of colorectal cancer and adenomas, or pre-cancerous polyps.
VNRX: 3.37 (-0.07)
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
PR Newswire - Fri May 13, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2016.
VNRX: 3.37 (-0.07)
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
PR Newswire - Thu May 12, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ® blood tests for the detection of pancreatic cancer.
VNRX: 3.37 (-0.07)
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
PR Newswire - Mon May 09, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended March 31, 2016, it will host a conference call on May 13, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 3.37 (-0.07)
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
PR Newswire - Wed Apr 20, 8:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers at 73% specificity1. The study was conducted in collaboration with the Surrey Cancer Research Institute at the University of Surrey in the UK. The results are being presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
VNRX: 3.37 (-0.07)
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
PR Newswire - Thu Apr 14, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Louise Day as its Chief Marketing and Communications Officer, effective April 11, 2016. Ms. Day will lead VolitionRx communications and develop the Company's branding and global marketing strategy in preparation for the initial market entry of its NuQ® blood-based tests for cancer. The Company expects to commence the European launch of NuQ® in 2016, to be followed by the U.S. and rest of the world.
VNRX: 3.37 (-0.07)
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
PR Newswire - Fri Apr 08, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that first results from a prostate cancer study by the Company will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology. The meeting is being held April 16-20, 2016 in New Orleans, LA.
VNRX: 3.37 (-0.07)
VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer
PR Newswire - Thu Apr 07, 6:08AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced CE marking for two blood-based diagnostic assays for the detection of colorectal cancer. The biomarker assays, NuQ®V001 and NuQ®T003, identify and analyze fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of cancer signatures.
VNRX: 3.37 (-0.07)
VolitionRx Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Mar 17, 3:01PM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. VolitionRx intends to grant the underwriters an option to purchase an additional 15% of the shares of common stock sold in the offering, to cover over-allotments, if any. All shares of common stock in the offering are being offered by VolitionRx. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
VNRX: 3.37 (-0.07)
VolitionRx Announces Full Year 2015 Financial Results and Business Update
PR Newswire - Fri Mar 11, 6:35AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the full year ended December 31, 2015.
VNRX: 3.37 (-0.07)
VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET
PR Newswire - Wed Mar 09, 7:30AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its annual report on Form 10-K for the year ended December 31, 2015, it will host a conference call on March 11, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 3.37 (-0.07)
Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
PR Newswire - Wed Mar 09, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today announced preliminary data from a pilot study demonstrating that the Company's NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF). This is the first set of results from a non-cancer trial of VolitionRx's NuQ® blood tests, which demonstrates the technology's potential as a diagnostic for other diseases.
VNRX: 3.37 (-0.07)
/C O R R E C T I O N -- VolitionRx Ltd/
PR Newswire - Thu Feb 04, 7:01AM CST
In the news release, VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection, issued 04-Feb-2016 by VolitionRx Ltd over PR Newswire, we are advised by the company that the link in the 6th paragraph should read "http://youtu.be/Z7qfaFxGnyY" rather than "https://youtu.be/Z7qfaFxGnyY" as originally issued inadvertently. The complete, corrected release follows:
VNRX: 3.37 (-0.07)
VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection
PR Newswire - Thu Feb 04, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today released a video to celebrate World Cancer Day and to offer a message of hope from the inspirational cancer survivor, explorer and campaigner, Sean Swarner. VolitionRx supported Swarner's most recent expedition to the South Pole as part of the Company's corporate social responsibility programme and to raise awareness of the importance of early detection of cancer, as well as to show that patients can lead a long full life after overcoming cancer.
VNRX: 3.37 (-0.07)
VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
PR Newswire - Tue Feb 02, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today announced that it has initiated a study to assess the feasibility of using the Company's NuQ® blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK.
VNRX: 3.37 (-0.07)
VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
PR Newswire - Thu Jan 28, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), today announced that the Company's subsidiary, Belgian Volition SA, has received the International Standards Organization (ISO) certification EN ISO 13485:2012 for its quality management system for the design, development, production and distribution of its NuQ® blood tests for a broad range of cancers.
VNRX: 3.37 (-0.07)
VolitionRx Releases Annual Shareholder Update Letter
PR Newswire - Wed Jan 13, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today released its annual update letter to its shareholders from CEO Cameron Reynolds. The letter provides a review of the Company's activities and milestones during 2015 and objectives for 2016.
VNRX: 3.37 (-0.07)
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
PR Newswire - Tue Jun 14, 6:02AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced full results from a prospective assessment of pre-analytical variables contributing to the accuracy of its NuQ® blood test that confirm the stability of circulating cell-free nucleosomes (cfnucleosomes) as biomarkers in cancer. The findings were published on 13th June 2016 in the article, "Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9me3" in the Scandinavian Journal of Clinical and Laboratory Investigation, an international scientific journal focused on clinically-orientated biochemical and physiological research.
VNRX: 3.37 (-0.07)
VolitionRx to Present at Two Upcoming Conferences in June
PR Newswire - Tue May 31, 8:16AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that the Company is scheduled to present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and at the LD Micro Invitational conference, being held June 7-9 in Los Angeles, CA.
VNRX: 3.37 (-0.07)
SeeThruEquity Issues Update Note on VolitionRx (NYSE MKT: VNRX) with a Price Target of $6.70
ACCESSWIRE - Mon May 23, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on VolitionRx Ltd. (NYSE MKT: VNRX).
VNRX: 3.37 (-0.07)
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
PR Newswire - Thu May 19, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that its Chief Medical Officer & Head of U.S. Operations, Dr. Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee Meeting on May 20, 2016, which precedes Digestive Disease Week (DDW), being held May 21-24, 2016 in San Diego, CA. Dr. Terrell will present data from three clinical trials evaluating the Company's NuQ® blood tests for the detection of colorectal cancer and adenomas, or pre-cancerous polyps.
VNRX: 3.37 (-0.07)
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
PR Newswire - Fri May 13, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2016.
VNRX: 3.37 (-0.07)
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
PR Newswire - Thu May 12, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ® blood tests for the detection of pancreatic cancer.
VNRX: 3.37 (-0.07)
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
PR Newswire - Mon May 09, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended March 31, 2016, it will host a conference call on May 13, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 3.37 (-0.07)
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
PR Newswire - Wed Apr 20, 8:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers at 73% specificity1. The study was conducted in collaboration with the Surrey Cancer Research Institute at the University of Surrey in the UK. The results are being presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
VNRX: 3.37 (-0.07)
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
PR Newswire - Thu Apr 14, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Louise Day as its Chief Marketing and Communications Officer, effective April 11, 2016. Ms. Day will lead VolitionRx communications and develop the Company's branding and global marketing strategy in preparation for the initial market entry of its NuQ® blood-based tests for cancer. The Company expects to commence the European launch of NuQ® in 2016, to be followed by the U.S. and rest of the world.
VNRX: 3.37 (-0.07)
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
PR Newswire - Fri Apr 08, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that first results from a prostate cancer study by the Company will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology. The meeting is being held April 16-20, 2016 in New Orleans, LA.
VNRX: 3.37 (-0.07)
VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer
PR Newswire - Thu Apr 07, 6:08AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced CE marking for two blood-based diagnostic assays for the detection of colorectal cancer. The biomarker assays, NuQ®V001 and NuQ®T003, identify and analyze fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of cancer signatures.
VNRX: 3.37 (-0.07)
VolitionRx Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Mar 17, 3:01PM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. VolitionRx intends to grant the underwriters an option to purchase an additional 15% of the shares of common stock sold in the offering, to cover over-allotments, if any. All shares of common stock in the offering are being offered by VolitionRx. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
VNRX: 3.37 (-0.07)
VolitionRx Announces Full Year 2015 Financial Results and Business Update
PR Newswire - Fri Mar 11, 6:35AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the full year ended December 31, 2015.
VNRX: 3.37 (-0.07)
VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET
PR Newswire - Wed Mar 09, 7:30AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its annual report on Form 10-K for the year ended December 31, 2015, it will host a conference call on March 11, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 3.37 (-0.07)
Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
PR Newswire - Wed Mar 09, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today announced preliminary data from a pilot study demonstrating that the Company's NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF). This is the first set of results from a non-cancer trial of VolitionRx's NuQ® blood tests, which demonstrates the technology's potential as a diagnostic for other diseases.
VNRX: 3.37 (-0.07)
/C O R R E C T I O N -- VolitionRx Ltd/
PR Newswire - Thu Feb 04, 7:01AM CST
In the news release, VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection, issued 04-Feb-2016 by VolitionRx Ltd over PR Newswire, we are advised by the company that the link in the 6th paragraph should read "http://youtu.be/Z7qfaFxGnyY" rather than "https://youtu.be/Z7qfaFxGnyY" as originally issued inadvertently. The complete, corrected release follows:
VNRX: 3.37 (-0.07)
VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection
PR Newswire - Thu Feb 04, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today released a video to celebrate World Cancer Day and to offer a message of hope from the inspirational cancer survivor, explorer and campaigner, Sean Swarner. VolitionRx supported Swarner's most recent expedition to the South Pole as part of the Company's corporate social responsibility programme and to raise awareness of the importance of early detection of cancer, as well as to show that patients can lead a long full life after overcoming cancer.
VNRX: 3.37 (-0.07)
VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
PR Newswire - Tue Feb 02, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX) today announced that it has initiated a study to assess the feasibility of using the Company's NuQ® blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK.
VNRX: 3.37 (-0.07)
VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
PR Newswire - Thu Jan 28, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), today announced that the Company's subsidiary, Belgian Volition SA, has received the International Standards Organization (ISO) certification EN ISO 13485:2012 for its quality management system for the design, development, production and distribution of its NuQ® blood tests for a broad range of cancers.
VNRX: 3.37 (-0.07)
VolitionRx Releases Annual Shareholder Update Letter
PR Newswire - Wed Jan 13, 6:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today released its annual update letter to its shareholders from CEO Cameron Reynolds. The letter provides a review of the Company's activities and milestones during 2015 and objectives for 2016.
VNRX: 3.37 (-0.07)
